| 中文名称: | 磺丁基醚-β-环糊精钠盐 热销 促销 | ||||
|---|---|---|---|---|---|
| 英文名称: | Sodium salt of butyl ether - β - cyclodextrin | ||||
| 别名: | β-环糊精磺丁基醚钠盐 SBE-β-CD | ||||
| CAS No: | 182410-00-0 | 分子式: | C50H84Na2O41S2 | 分子量: | 1451.29 |
| CAS No: | 182410-00-0 | ||||
| 分子式: | C50H84Na2O41S2 | ||||
| 分子量: | 1451.29 | ||||
基本信息
|
产品编号： |
S10001 |
||||
|
产品名称： |
Sodium salt of butyl ether-β-cyclodextrin |
||||
|
CAS: |
182410-00-0 |
储存条件 |
粉末 |
室温 |
四年 |
|
|
|
||||
|
分子式： |
溶于液体 |
-80℃ |
两年 |
||
|
分子量 |
1451.29 |
|
|
||
|
化学名： |
|
||||
|
Solubility (25°C)： |
|||||
|
体外:
|
DMSO |
Insoluble |
|||
|
Ethanol |
Insoluble |
||||
|
Water |
100mg/mL |
||||
|
体内(现配现用): |
|
||||
|
＜1mg/ml表示微溶或不溶。 |
|||||
|
普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。 |
|||||
|
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 |
|||||
生物活性
|
产品描述 |
能很好地与药物分子包合形成非共价复合物，从而提高药物的稳定性、水溶性、安全性，降低肾毒性、缓和药物溶血性，控制药物释放速率，掩盖不良气味等。 |
|
体外研究 |
SBE-β-CD is a chemically modified β-CD that is a cyclic hydrophilic oligosaccharide which is negatively charged in aqueous media. β-CD functioned is a solubilizer only at low concentrations, whereas SBE7-β-CD exhibits strong solubilizing effects over a wide concentration range |
|
体内研究 |
20% SBE-β-CD in saline: Guidelines (Following is our recommended protocol. This protocol only provides a guideline, and should be modified according to your specific needs). 1. Dissolve 0.9 g of NaCl in 100mL distilled water to make a clear 0.9% saline solution. 2. Measure 2 g of dry SBE-β-CD. 3. Dissolve 2 g of SBE-β-CD in 0.9% saline to make 10mL with a 20% (w/v) concentration. These may require ultrasonic (20- 40 kHz, 30 seconds, repeat 3 times) or heating (37°C for about 30 minutes). If precipitation is observed, the precipitates can be dissolved by heating to 37°C and vortexing before use. |
推荐实验方法(仅供参考)
|
Animal Administration |
Rats A 300g rat is administered with 1mL of a 0.1 M SBE-β-CD solution containing 5.64mg of Compound 1, and assuming an extracellular volume of 90mL, less than 0.1% of the complex would rapidly dissociate due to the initial effects of dilution. This calculation, combined with the changing blood to plasma ratio in the presence of SBE-β-CD, provides a reasonable explanation for the observed differences in the blood and plasma profiles of Compound 1 after intravenous administration in either the cyclodextrin or cyclodextrin-free formulations. After IV administration of the cyclodextrin formulation,Compound 1 would initially be prevented from distributing into erythrocytes thereby resulting in a whole blood to plasma ratio of less than one. Subsequently, clearance of SBE-β-CD from the circulation would lead to changes in the complexation equilibrium such that the unbound fraction of Compound 1 would increase, thereby reestablishing normal blood to plasma partitioning (i.e. in favour of whole blood) and clearance. |
本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为：
质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)
摩尔浓度计算公式
用本工具协助配置特定浓度的溶液，使用的计算公式为：
开始浓度 x 开始体积 = 最终浓度 x 最终体积
稀释公式
稀释公式一般简略地表示为：C1V1 = C2V2 ( 输入 输出 )
